Dukoral market set to grow as travel and cholera risk rise

The Dukoral market is expanding as global travel, cholera outbreaks and concern over waterborne disease lift demand for preventive vaccines. The Business Research Company says Asia-Pacific was the largest regional market in 2025, while new report features point to a more data-heavy outlook through 2035.

Why it matters: - Dukoral is an oral vaccine used by travelers and others at risk of cholera and certain ETEC-related diarrhea. - Rising cholera incidence, climate-related spread and stronger traveler health precautions are increasing demand for preventive vaccines. - The market’s trajectory matters for travel medicine providers, public health planning and vaccine manufacturers.

What happened: - The Business Research Company released a competitive landscape report on the Dukoral global market covering size, trends and forecasts for 2026-2035. - The report says the Dukoral market has grown on the back of historical cholera outbreaks, international travel, government vaccination recommendations and wider use of travel health clinics. - The company says Asia-Pacific was the largest regional market for Dukoral in 2025. - The report also covers Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample and a full version available through the company’s sample request page and the full report page.

The details: - Dukoral contains inactivated cholera toxin and a recombinant cholera toxin B subunit. - The vaccine is designed to prevent cholera and certain types of diarrhea caused by ETEC bacteria. - The report points to growing global travel as a major demand driver. - Climate change is helping cholera spread into new areas, adding pressure to prevention efforts. - Preventive healthcare investment and oral vaccine technology improvements are also supporting market growth. - Public awareness of cholera and enterotoxigenic Escherichia coli is contributing to demand. - The report says broader acceptance of oral vaccines is a key trend because they are convenient and non-invasive. - The World Health Organization reported in 2023 a 13% increase in cholera cases worldwide and a 71% increase in deaths compared with 2022, with more than 4,000 fatalities.

Between the lines: - The report frames Dukoral as part of a wider shift toward travel-linked prevention, not just outbreak response. - Climate change and sanitation gaps are expanding the practical need for vaccine-based protection in more regions. - The report’s added market-scoring tools suggest investors and suppliers are being pushed toward more granular regional and competitive analysis.

What's next: - The market is expected to benefit from more international travel and continued concern over travel-related infections. - Wider use of oral vaccines could support adoption if convenience continues to matter in traveler decision-making. - The report says future growth will also depend on preventive healthcare spending and continued innovation in oral vaccine technology. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and key technology and future trend analysis.